A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Bleximenib, Venetoclax and Azacitidine for Newly Diagnosed AML Harboring KMT2A Rearrangements or NPM1 Mutations Ineligible for Intensive Chemotherapy